IMV Inc. to Present at Two Upcoming Investor Events

Rhea-AI Summary

IMV Inc. (NASDAQ: IMV; TSX: IMV) announced that its executive team will present at the Biotech Showcase 2022 from January 10-12 and at the H.C. Wainwright Bioconnect 2022 from January 10-13. Their presentation will be available on January 10 via their website. IMV develops immune-educating therapies using the DPX platform targeting solid and hematological cancers.

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today announced that members of IMV’s executive management team will be presenting virtually at the Biotech Showcase^TM 2022 investor conference which will be held January 10-12 and at the H.C. Wainwright Bioconnect 2022 conference held January 10-13.

A copy of IMV’s presentation for both of these events will be made available in the ‘Events, Webcasts & Presentations' section of IMV’s website on the morning of January 10, 2022. Additionally, a webcast link to the H.C. Wainwright Bioconnect 2022 conference will also be available at 7:00 AM EST on January 10.

About IMV

IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX™ technology. Through a differentiated mechanism of action, the DPX platform delivers instructions to the immune system and generates a specific, robust, and persistent immune response. IMV’s lead candidate, maveropepimut-S (MVP-S) delivers antigenic peptides of survivin, a well-recognized cancer antigen. Treatments with MVP-S have demonstrated the activation of a targeted and sustained anti-tumor immune response, correlated with clinical benefit and have been well tolerated across all clinical trials. MVP-S is currently being evaluated in clinical trials for blood and solid cancers, including in Diffuse Large B Cell Lymphoma (DLBCL) as well as ovarian, bladder and breast cancers. IMV is also developing a second immunotherapy leveraging the DPX immune delivery platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously. A Phase 1 clinical trial in bladder cancer will open early 2022. For more information, visit www.imv-inc.com and connect with us on Twitter and LinkedIn.

IMV Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements use such word as “will”, “may”, “potential”, “believe”, “expect”, “continue”, “anticipate” and other similar terminology. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements regarding the Company’s ability to advance its development strategy, as well as the prospects, for its lead immunotherapy and its other pipeline of immunotherapy candidates. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful design and completion of clinical trials and the timely receipt of all regulatory approvals to commence, and then continue, clinical studies and trials and the receipt of all regulatory approvals to commercialize its products. IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and uncertainties, and those risks and uncertainties include, but are not limited to, the ability to access capital, the successful and, generally, the timely completion of clinical trials and studies and the receipt of all regulatory approvals as well as other risks detailed from time to time in our ongoing quarterly filings and annual information form. Investors are cautioned not to rely on these forward-looking statements and are encouraged to read IMV’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005322/en/

Investor Relations

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.

O: (902) 492-1819 ext : 1042

M: (514) 617-9481

E: mjasmin@imv-inc.com

Irina Koffler, Managing Director, LifeSci Advisors

O: (646) 970-4681

M: (917) 734-7387

E: ikoffler@lifesciadvisors.com

Media

Delphine Davan, Senior Director, Communications, IMV Inc.

M: (514) 968 1046

E: ddavan@imv-inc.com

Madeline Joanis, Senior Account Executive, LifeSci Communications

M: (603) 479 5267

E: mjoanis@lifescicomms.com

Source: IMV Inc.

FAQ

When will IMV present at the Biotech Showcase 2022?

IMV will present at the Biotech Showcase 2022 from January 10-12.

What is the focus of IMV's DPX platform?

IMV's DPX platform focuses on developing immune-educating therapies for solid and hematological cancers.

What dates is the H.C. Wainwright Bioconnect 2022 conference?

The H.C. Wainwright Bioconnect 2022 conference will take place from January 10-13.

Where can I find IMV's presentation materials?

IMV's presentation materials will be available in the 'Events, Webcasts & Presentations' section of their website on January 10.

What cancers are targeted by IMV's lead candidate MVP-S?

IMV's lead candidate, MVP-S, targets cancers such as Diffuse Large B Cell Lymphoma, ovarian, bladder, and breast cancers.